Please login to the form below

Not currently logged in

FDA panel backs Novartis' secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials
Novartis building

Novartis moved a step closer to US approval for its psoriasis candidate secukinumab after an FDA advisory committee gave unanimous support for the drug yesterday.

Secukinumab - currently leading the field among a new class of anti-interleukin-17 (IL-17) inhibitors - should be approved for the treatment of moderate-to-severe plaque psoriasis in adults who need systemic treatment for the skin disorder, said the panellists.

Like other IL17 inhibitors, secukinumab has been shown to be very effective in clearing psoriasis plaques in clinical trials, outperforming Amgen's TNF antagonist Enbrel (etanercept), one of the most widely-used biologic therapies for the disease. It shows consistent activity regardless of the severity of symptoms.

A green light from the advisory committee puts Novartis on track for US approval of secukinumab in early 2015, ahead of rival IL-17 inhibitors such as Eli Lilly's ixekizumab and Amgen/AstraZeneca's brodalumab, which have both clear phase III trials and are due to be filed in the coming months. Secukinumab has also been filed for approval in Europe and Japan.

Vas Narasimhan, global head of development at Novartis, said: "There is a need for novel therapies [for psoriasis] as not all treatments are appropriate or effective in every patient. We look forward to working with the FDA as it finalises its review."

The IL-17 inhibitors are expected to eat into the share of the psoriasis market held by TNF blockers as they seem not only to have superior efficacy - with a greater proportion of patients getting complete clearance of symptoms - but are also better-tolerated with no major safety issues identified in clinical trials to date.

Analysts see the greatest competition for the new class coming not from the TNF blockers but other new psoriasis therapies. These include Johnson & Johnson's big-selling IL-12/IL-23 inhibitor Stelara (ustekinumab) - which grew 40% to top $1.5bn in sales in the first nine months of 2014 - as well as Celgene's orally-active phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast), which was approved for psoriasis last month and has been tipped to become a $1bn-plus product at peak.

Coming up from the rear is J&J's anti-IL-23 drug guselkumab, a more selective Stelara follow-up, which has started phase III testing and promises to have an improved clinical profile compared to its predecessor.

Article by
Phil Taylor

21st October 2014

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...